

Unravelling molecular and biochemical dysfunction by Shiga toxin: implication for thrombotic microangiopathy in Hemolytic Uremic Syndrome

Citation for published version (APA):

Morigi, M. (2006). *Unravelling molecular and biochemical dysfunction by Shiga toxin: implication for thrombotic microangiopathy in Hemolytic Uremic Syndrome*. [Doctoral Thesis, Maastricht University]. Universiteit Maastricht. <https://doi.org/10.26481/dis.20060316mm>

Document status and date:

Published: 01/01/2006

DOI:

[10.26481/dis.20060316mm](https://doi.org/10.26481/dis.20060316mm)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Download date: 13 Feb. 2025

STELLINGEN

behorende bij het proefschrift

Unravelling molecular and biochemical dysfunction by Shiga toxin: implication for thrombotic microangiopathy in Hemolytic Uremic Syndrome.

Marina Morigi

- Infection with Verotoxin/ Shiga toxin-producing *E. coli* is the most common causative agent of the epidemic form of Hemolytic Uremic Syndrome, the major cause of acute renal failure in children. Endothelial injury has been recognized as the trigger event in the development of microangiopathic process.

(This thesis)

- Shiga toxin-1 modulates *in vitro* leukocyte - endothelium interaction under flow conditions by increasing leukocyte adhesion and upregulating adhesive molecules on endothelial surface.

(This thesis)

- Microvascular endothelial cells change their normal thromboresistant phenotype in response to Shiga toxin-1 and become thrombogenic under high shear stress, via the upregulation of endothelial adhesive proteins.

(This thesis)

- Shiga toxin-2 via transcriptional activation mechanism mediated by NF- κ B induces endothelial MCP-1 and IL-8, chemokines involved in leukocyte adhesion and transmigration.

(This thesis)

- In response to plasma protein load glomerular podocytes reorganize actin cytoskeleton network and modulate endothelin-1 gene expression.

(This thesis)

- Podocyte is a functionally relevant target of Shiga toxin-2 that via the upregulation of endothelin gene, induces podocyte activation and cytoskeletal derangement. These changes may contribute to glomerular dysfunction in epidemic form of Hemolytic Uremic Syndrome.

(This thesis)

- Abnormal traffic of proteins through the glomerular capillary barrier has an intrinsic renal toxicity linked to their over-reabsorption by proximal tubular epithelial cells and activation of tubular-dependent pathways of interstitial inflammation.

- Stem cells from adult and embryonic sources have great therapeutic potential, but much research is still needed before their clinical use becomes commonplace.

- Bone marrow-derived mesenchymal stem cells, by virtue of their renotropic properties and tubular regenerative potential may have a role in the treatment of acute renal failure.

- Scientists of developed world may help in shaping scientific institution and training a new generation of health professional in developing countries.

THE WALL STREET JOURNAL

